Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 101Radiotherapy 50Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 23Bevacizumab 23Lomustine 16Nivolumab 14Surgical Procedures, Operative 11atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7Carboplatin 7fludarabine 6Radiotherapy, Intensity-Modulated 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5regorafenib 4poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × vocimagene amiretrorepvec × 1 year × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡